Justdapa-M 10/1000 Tablet ER is a combination oral antidiabetic medication containing Dapagliflozin 10 mg and Metformin 1000 mg in an extended-release formulation. It is indicated for the management of type 2 diabetes mellitus to improve glycemic control in adults when diet and exercise alone do not provide adequate control. Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting urinary glucose excretion and thereby lowering blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake. The extended-release formulation allows for once-daily dosing, improving patient compliance and maintaining steady plasma drug concentrations. Justdapa-M 10/1000 Tablet ER should be used with caution in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Common adverse effects include urinary tract infections, genital mycotic infections, gastrointestinal disturbances, and rare cases of lactic acidosis. Regular monitoring of renal function and blood glucose levels is recommended during therapy. This combination therapy offers a complementary mechanism of action, providing effective glycemic control while potentially aiding in weight reduction and cardiovascular risk mitigation in patients with type 2 diabetes.